Lupin launches generic Axiron
Lupin has introduced its generic Axiron (testosterone topical solution). The company had previously received approval from the Food and Drug Administration for the product, which is indicated for replacement therapy in males for conditions associated with deficient or absent endogenous testosterone.
Lupin’s generic Axiron will be available in a dosage strength of 30 mg per actuation. The product had a market size of $179 million for the 12 months ended December 2017, according to IQVIA data.
Lupin’s generic Axiron will be available in a dosage strength of 30 mg per actuation. The product had a market size of $179 million for the 12 months ended December 2017, according to IQVIA data.